Hostname: page-component-848d4c4894-tn8tq Total loading time: 0 Render date: 2024-07-02T13:49:58.868Z Has data issue: false hasContentIssue false

Clinical and immunological profile of patients with schizophrenia

Published online by Cambridge University Press:  01 September 2022

N. Petrova*
Affiliation:
Saint-Petersburg State University, Department Of Psychiatry And Addiction, Saint-Petersburg, Russian Federation
M. Mayorova
Affiliation:
Saint Petersburg State University, Laboratory Of Mosaic Of Autoimmunity, Saint-Petersburg, Russian Federation
L. Churilov
Affiliation:
Saint Petersburg State University, Laboratory Of Mosaic Of Autoimmunity, Saint-Petersburg, Russian Federation
A. Gvozdetskiy
Affiliation:
North-western State Medical university named after I. I. Mechnikov, Chair Of Psychiatry And Addiction, Saint-Petersburg, Russian Federation
I. Kudryavtsev
Affiliation:
FSBSI Institute of experimental medicine, Department Of Immunology, Saint-Petersburg, Russian Federation
P. Sobolevskaia
Affiliation:
Saint Petersburg State University, Laboratory Of Mosaic Of Autoimmunity, Saint-Petersburg, Russian Federation
V. Serazetdinova
Affiliation:
Saint-Petersburg FSBI Psychoneurological dispensary № 5, Day Hospital Department, Saint-Petersburg, Russian Federation
*
*Corresponding author.

Abstract

Core share and HTML view are not available for this content. However, as you have access to this content, a full PDF is available via the ‘Save PDF’ action button.
Introduction

The question of the involvement of inflammatory and autoimmune processes in schizophrenia pathogenesis has become the most relevant in the last decade and yet is not fully understood.

Objectives

The study included 60 patients with paranoid schizophrenia (age 18 - 55 y.o.) and 30 healthy control group participants. Patients were in a stabilization state without a history of organic brain disorder or another verified somatic disease in the exacerbation phase.

Methods

Research methods included follow-up method, neuropsychological (PANSS, BAC-S), laboratory (enzyme immunoassay, flow cytometry), and statistical.

Results

Patients with schizophrenia had significant structural disorders of thinking, passive, apathetic withdrawal, negativism, impaired attention, psychomotor speed, volitional impulses. Cognitive impairment was detected in all study participants. Severe impairments are noted in the executive functioning, hand-eye coordination, attention, psychomotor speed. The severity of cognitive impairments correlated with the severity of clinical symptoms. Patients with schizophrenia had a significant decrease in central memory T-regulators levels, and an increase in Th1 and Th2 subsets, «double-positive» and «сlassic» Th17, Tfh2, «classic» Tfh17, and in Tfh17.1 (Pic.1).

Picture. 1. T-helper subsets in patients with schizophrenia. They also had high levels of CCL20, IL-10, IL-12, IL-1β, IL-27, IL-31, IL-4, IL-13, IL-6, IL-9, TNFα in comparison with a control group. A significantly decreased levels of IL-17A, IL-17F, IL-2, IL-22, and TNFβ were also described in this group of patients.

Conclusions

Patients with schizophrenia may be characterized by the presence of an inflammatory process and a high chance of autoimmunity. Aknowledgement. This work was supported by the grant of the Russian Federation Government, contract 14.W03.31.0009

Disclosure

No significant relationships.

Type
Abstract
Creative Commons
Creative Common License - CCCreative Common License - BY
This is an Open Access article, distributed under the terms of the Creative Commons Attribution licence (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted re-use, distribution, and reproduction in any medium, provided the original work is properly cited.
Copyright
© The Author(s), 2022. Published by Cambridge University Press on behalf of the European Psychiatric Association
Submit a response

Comments

No Comments have been published for this article.